Bulletin
Investor Alert

New York Markets Open in:

Aug. 6, 2020, 6:45 a.m. EDT

Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)

or Cancel Already have a watchlist? Log In

GAITHERSBURG, Md., Aug 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- Novavax, Inc. /zigman2/quotes/202614340/composite NVAX +0.86% , a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Conference call details are as follows:







        Date:           August 10, 2020
        Time:           4:30 p.m. U.S. Eastern Time (ET)
        Dial-in number: (877) 923-9376 (Domestic) or (720) 545-0026 (International)
        Passcode:       3048947
        Webcast:        www.novavax.com, "For Investors"/ "Events"
        


Conference call and webcast replay:







        Dates:          Starting at 7:30 p.m. ET, August 10, 2020 until 7:30 p.m. ET August 17, 2020
        Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
        Passcode:       3048947
        Webcast:        www.novavax.com, "For Investors"/ "Events", until November 10, 2020
        


About Novavax

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX +0.86% is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX�?'CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 portion of the Phase 1/2 clinical trial. NanoFlu(TM), its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors

Silvia Taylor and Erika Trahan

ir@novavax.com

240-268-2022

Media

Amy Speak

amy@speaklifescience.com

617-420-2461

https://ml.globenewswire.com/media/5b9ff71d-d7a5-4d87-baef-c8cc6ff25088/small/novavax-logo.jpg

COMTEX_368968549/2010/2020-08-06T06:45:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 102.44
+0.87 +0.86%
Volume: 3.34M
Sept. 24, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.22 billion
Rev. per Employee
$90,470
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 102.44
+0.87 +0.86%
Volume: 3.34M
Sept. 24, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.22 billion
Rev. per Employee
$90,470
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.